A Look at Atai Life Sciences (ATAI) Valuation Following Breakthrough Therapy FDA Nod and $149.5M Capital Raise

Simply Wall St.

Oct 23

Atai Life Sciences (NasdaqGM:ATAI) just wrapped up a public offering, netting about $149.5 million to drive its clinical pipeline forward. This new funding will support Phase 3 and Phase 2 trials, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2577181883"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577181883\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577181883?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2025-10-23 01:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577181883","market":"nz","top_or_hot":-1,"title":"A Look at Atai Life Sciences (ATAI) Valuation Following Breakthrough Therapy FDA Nod and $149.5M Capital Raise","media":"Simply Wall St.","content":"<div>\n<p>Atai Life Sciences (NasdaqGM:ATAI) just wrapped up a public offering, netting about $149.5 million to drive its clinical pipeline forward. This new funding will support Phase 3 and Phase 2 trials, ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-atai/atai-life-sciences/news/a-look-at-atai-life-sciences-atai-valuation-following-breakt\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look at Atai Life Sciences (ATAI) Valuation Following Breakthrough Therapy FDA Nod and $149.5M Capital Raise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look at Atai Life Sciences (ATAI) Valuation Following Breakthrough Therapy FDA Nod and $149.5M Capital Raise\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-23 01:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-atai/atai-life-sciences/news/a-look-at-atai-life-sciences-atai-valuation-following-breakt><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Atai Life Sciences (NasdaqGM:ATAI) just wrapped up a public offering, netting about $149.5 million to drive its clinical pipeline forward. This new funding will support Phase 3 and Phase 2 trials, ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-atai/atai-life-sciences/news/a-look-at-atai-life-sciences-atai-valuation-following-breakt\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-atai/atai-life-sciences/news/a-look-at-atai-life-sciences-atai-valuation-following-breakt","article_id":"2577181883","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-atai/atai-life-sciences/news/a-look-at-atai-life-sciences-atai-valuation-following-breakt","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2577181883","pubTimestamp":1761154443,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Atai Life Sciences (NasdaqGM:ATAI) just wrapped up a public offering, netting about $149.5 million to drive its clinical pipeline forward. This new funding will support Phase 3 and Phase 2 trials, with operations expected to be covered through 2029.\nThe timing is striking, as the capital comes shortly after the FDA granted Breakthrough Therapy designation to Atai’s BPL-003 nasal spray for treatment-resistant depression. This regulatory milestone is designed to accelerate development and...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4539":"次新股","ATAI":"Atai Beckley Inc"},"translate_title":"FDA批准突破性疗法并筹集1.495亿美元融资后Atai Life Sciences(ATAI)估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATAI":1.5},"content_text":"Atai Life Sciences (NasdaqGM:ATAI) just wrapped up a public offering, netting about $149.5 million to drive its clinical pipeline forward. This new funding will support Phase 3 and Phase 2 trials, with operations expected to be covered through 2029. The timing is striking, as the capital comes shortly after the FDA granted Breakthrough Therapy designation to Atai’s BPL-003 nasal spray for treatment-resistant depression. This regulatory milestone is designed to accelerate development and review, providing investors with fresh reasons to follow the company’s progress. See our latest analysis for Atai Life Sciences. Atai Life Sciences’ share price has surged an impressive 266.9% year-to-date, backed by major milestones like the FDA’s Breakthrough Therapy nod for BPL-003 and the successful $149.5 million capital raise. Momentum has really taken off over the past quarter, as reflected in a 51.3% three-month share price return, while total shareholder return for the past year stands at a remarkable 358.6%. That’s a level of performance that’s tough to ignore, especially as investor sentiment has swung firmly toward optimism with clinical catalysts finally in play. If these rapid gains have you curious about the next big opportunities in the sector, consider exploring See the full list for free. With shares soaring and a major FDA milestone in hand, the key question now is whether Atai Life Sciences’ recent gains leave the stock undervalued or if the market has already priced in all the future growth potential. AdvertisementPrice-to-Book of 8.8x: Is it justified? Atai Life Sciences trades at a price-to-book (P/B) ratio of 8.8x, which puts it well above the typical valuation of US pharmaceutical companies. With the last close at $5.87, the market appears to be assigning a premium to the company’s assets. The price-to-book ratio measures how much investors are willing to pay for each dollar of net assets on the balance sheet. For early-stage or high-growth biotech firms like Atai, a high P/B can reflect potential future breakthroughs or anticipated revenue growth, even if current profits are lacking. Compared to the US pharmaceuticals industry average P/B of 2.3x, Atai’s valuation looks expensive. This level of premium means investors are betting heavily on clinical progress or future earnings. The market is assigning far more value to Atai’s pipeline than to the typical peer, which could reflect enthusiasm about their trial milestones and growth outlook. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-Book of 8.8x (OVERVALUED) However, setbacks in clinical trials or regulatory delays could quickly reverse momentum. This reminds investors that biotech breakthroughs always come with meaningful risk. Find out about the key risks to this Atai Life Sciences narrative.  Build Your Own Atai Life Sciences Narrative If this perspective does not align with your own, or you prefer to dive into the details yourself, it’s easy to form your own narrative in just a few minutes. Do it your way A great starting point for your Atai Life Sciences research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision. Looking for More Smart Investment Opportunities? Don’t let the momentum stop here. Access powerful stock ideas that could turn into tomorrow’s surprises, curated to help you stay ahead of the market’s next big moves.  Unlock higher yields by targeting top performers with generous payouts by checking out these 17 dividend stocks with yields > 3%. Catch the next wave of innovation by scanning these 25 AI penny stocks making headlines for breakthroughs in artificial intelligence and game-changing automation. Spot hidden value by reviewing these 875 undervalued stocks based on cash flows, where strong financials may signal untapped upside before the crowd catches on.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}